On April 2, the National Institutes of Health awarded CinderBio a $1.6M Phase II SBIR to commercialize its proteomics enzymes over the next two years.
Proteomics is the broad study of proteins that is transitioning from R&D applications to more applied fields such as clinical applications and diagnostics. The mass-spectrometry based proteomics market is projected to be worth over $10B by 2022.
(From CinderBio newsletter, July 16, 2020)